Research and development initiatives have long acknowledged that patient participation in clinical research is driven by “hope for a cure” as a key incentive
Patient reported outcomes, subgroup analyses, “exit” interviews at study conclusions, help contextualize the value of trial data within a scientific, clinical, and humanistic framework
Within oncology indications particularly, selective patient targeting, innovative trial designs to accelerate approval, and assessments that reflect how patients “feel, function or survive” are highlighted as distinguishing characteristics.
